Concepedia

PKI-179: An orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor

Aranapakam M. Venkatesan, Zecheng Chen, Osvaldo dos Santos, Christoph M. Dehnhardt, Efren Delos Santos, Semiramis Ayral‐Kaloustian, Robert Mallon, Irwin Hollander, Larry Feldberg, Judy Lucas,

Bioorganic & Medicinal Chemistry Letters · 2010 · 71 citations · 17 references

DOIFull text

Open access

Concepts

References

17

A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002).

Chris J. Vlahos, William F. Matter, K. Y. Hui et al. · Journal of Biological Chemistry · 1994 · 3.3K citations · Full text

, , +16

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity

Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen et al. · Molecular Cancer Therapeutics · 2008 · 1.1K citations · Full text

, , +13

The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Adrian Folkes, Khatereh Ahmadi, W. Alderton et al. · Journal of Medicinal Chemistry · 2008 · 746 citations · Full text

, , +13

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.

Ker Yu, Lourdes Toral‐Barza, Carolyn Discafani et al. · Endocrine Related Cancer · 2001 · 418 citations · Full text

, , +17

Antitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor

Shin‐ichi Yaguchi, Yasuhisa Fukui, Ichiro Koshimizu et al. · JNCI Journal of the National Cancer Institute · 2006 · 388 citations · Full text

, , +14